Loading…
10x Genomics, Inc. is projected to rise to $51.65 by 2027, a +21% move from its current price of $42.73. TXG is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $40.94 | $42.76 | $44.65 | +0.06% |
| Jul 14 | $40.23 | $42.78 | $45.49 | +0.12% |
| Jul 15 | $39.70 | $42.81 | $46.15 | +0.18% |
| Jul 16 | $39.27 | $42.83 | $46.72 | +0.24% |
| Jul 17 | $38.89 | $42.86 | $47.23 | +0.30% |
| Jul 18 | $38.56 | $42.88 | $47.70 | +0.36% |
| Jul 19 | $38.25 | $42.91 | $48.14 | +0.42% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $38.25 | $42.91 | $48.14 | +0.42% |
| Week 2 | $36.63 | $43.09 | $50.69 | +0.84% |
| Week 3 | $35.46 | $43.27 | $52.80 | +1.27% |
| Week 4 | $34.53 | $43.45 | $54.68 | +1.69% |
| Week 5 | $33.75 | $43.64 | $56.42 | +2.12% |
| Week 6 | $33.07 | $43.82 | $58.06 | +2.55% |
| Week 7 | $32.47 | $44.00 | $59.64 | +2.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits.
It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides.
In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves academic, government, biopharmaceutical, biotechnology, and other institutions.
The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
TXG is a healthcare sector asset with a current price of $43.10 and a market capitalization of $5.47B. It holds a rank of 1318 by market capitalization.
The forecast landscape shows a path of rising average prices from 2026 onward, with 2026 average at $43.10, 2030 average at $113.28, 2040 average at $277.97, and 2050 average at $730.89, reflecting a bullish longer-term outlook.
Across the horizon, the forecast also shows rising min/max values and progressively larger ROIs, with 2027 avg $51.82 (ROI 20.2), 2028 avg $74.06 (ROI 71.8), 2029 avg $96.60 (ROI 124.1), 2030 avg $113.28 (ROI 162.8), 2040 avg $277.97 (ROI 544.9), and 2050 avg $730.89 (ROI 1595.8). The overall tone is bullish through 2050, based on the provided figures.
A major floor 60.9% below — a decisive break under it would weaken the trend.
The nearest floor, 34.5% below — buyers have tended to step in here.
Price is pressing into resistance (0.9% away) — a breakout level to watch.
A major ceiling 24.2% above — clearing it would confirm fresh momentum.
Key TXG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TXG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $40.23 | Buy | $40.74 | Buy |
| MA 10 | $39.14 | Buy | $39.07 | Buy |
| MA 20 | $35.77 | Buy | $36.41 | Buy |
| MA 50 | $29.28 | Buy | $31.29 | Buy |
| MA 100 | $25.23 | Buy | $26.99 | Buy |
| MA 200 | $20.81 | Buy | $22.82 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 72.06 | Sell |
| Stoch RSI (14) | 84.24 | Sell |
| CCI (20) | 137.47 | Buy |
| Williams %R (14) | -3.29 | Info |
| MACD (12,26,9) | 0.36 | Buy |
| ROC (12) | 34.08 | Buy |
| Bollinger %B (20,2) | 0.94 | Neutral |
| Stochastic %K (14) | 96.71 | Sell |
| TRIX (15) | 1.46 | Buy |
| Awesome (5,34) | 7.40 | Buy |
| Ultimate (7,14,28) | 70.65 | Sell |
| Momentum (10) | 7.00 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 41.19 | Buy |
| ADX (14) | 34.40 | Buy |
| ATR (14) | 1.37 | Info |
The 30-day technical picture is bullish. RSI(14) stands at 70, signaling strong near-term momentum. The 50-day simple moving average is $28.85 and the 200-day simple moving average is $20.66, suggesting an uptrend relative to longer-term averages.
Support is indicated at $25.51 and resistance at $43.10, with a 30-day price range from a low of $32.09 to a high of $57.89. The stock shows a bullish tilt in the near term based on these indicators.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.62 | $42.73 | $60.59 | 0% | Neutral | |
| $38.87 | $51.65 | $73.79 | +21% | Bullish | |
| $52.34 | $72.93 | $109.99 | +71% | Bullish | |
| $66.03 | $95.77 | $150.60 | +124% | Bullish | |
| $74.83 | $112.50 | $183.17 | +163% | Bullish | |
| $77.59 | $120.58 | $202.32 | +182% | Bullish | |
| $81.70 | $131.01 | $225.76 | +207% | Bullish | |
| $85.73 | $141.65 | $250.03 | +232% | Bullish | |
| $85.65 | $145.63 | $262.77 | +241% | Bullish | |
| $109.83 | $192.03 | $353.58 | +349% | Bullish | |
| $139.78 | $278.69 | $557.97 | +552% | Bullish | |
| $330.71 | $734.92 | $1,657.26 | +16.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.62 | $42.73 | $53.54 | +0.00% |
| August 2026 | $38.64 | $46.34 | $57.58 | +8.45% |
| September 2026 | $37.21 | $45.13 | $57.05 | -2.61% |
| October 2026 | $36.11 | $44.23 | $56.72 | -2.00% |
| November 2026 | $37.28 | $46.05 | $59.77 | +4.12% |
| December 2026 | $37.10 | $46.18 | $60.59 | +0.28% |
Click any year to see its month-by-month TXG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect TXG to range from $16.62 to $60.59 through 2026. The $42.73 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The TXG price prediction for 2027 points to an average of $51.65 (low $38.87, high $73.79) — a potential gain of +21% on today's $42.73. Buyers look set to stay in control over this stretch.
In 2028, TXG is projected to trade between $52.34 and $109.99, averaging $72.93 — a potential gain of +71% from today's $42.73. That is up +41% on the projected 2027 average. Momentum favours further upside here.
10x Genomics, Inc.'s 2029 outlook centres on $95.77, within a $66.03 to $150.60 range. That is up +31% on the projected 2028 average. That marks a +124% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, TXG could reach as high as $183.17, with a base case around $112.50 and support toward $74.83 — roughly +163% from $42.73. Momentum favours further upside here.
Expect TXG to range from $77.59 to $202.32 through 2031. The $120.58 average target implies a +182% move from current prices. That is up +7% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The TXG price prediction for 2032 points to an average of $131.01 (low $81.70, high $225.76) — a potential gain of +207% on today's $42.73. Momentum favours further upside here.
In 2033, TXG is projected to trade between $85.73 and $250.03, averaging $141.65 — a potential gain of +232% from today's $42.73. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
10x Genomics, Inc.'s 2034 outlook centres on $145.63, within a $85.65 to $262.77 range. That is up +3% on the projected 2033 average. That marks a +241% change versus current levels. Momentum favours further upside here.
By 2035, TXG could reach as high as $353.58, with a base case around $192.03 and support toward $109.83 — roughly +349% from $42.73. Buyers look set to stay in control over this stretch.
Expect TXG to range from $139.78 to $557.97 through 2040. The $278.69 average target implies a +552% move from current prices. That is up +45% on the projected 2035 average. Momentum favours further upside here.
The TXG price prediction for 2050 points to an average of $734.92 (low $330.71, high $1,657.26) — a potential gain of +16.2x on today's $42.73. Buyers look set to stay in control over this stretch.
Investing $1,000 in TXG today (≈ 23.402762 TXG) could be worth
$17,199.1
+$16,199.1 (+1620%) by 2050 · US Dollar
Based on the average projected TXG price of $734.92 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TXGwould be worth at today's price.
$1,000 invested in TXG on Jul 10, 2025 (≈ 79.239303 TXG) would be worth
$3,385.9
+$2,385.9 (+238.6%) today · 3.39× · US Dollar
Based on a TXG entry price of $12.62 vs. today's $42.73.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $39.01 | $1,095.36 | +9.5% |
| 1 month ago | $29.11 | $1,467.88 | +46.8% |
| 3 months ago | $23.27 | $1,836.27 | +83.6% |
| 6 months ago | $19.8 | $2,158.08 | +115.8% |
| 1 year ago | $12.62 | $3,385.9 | +238.6% |
| All time (5.0y) ago | $181.32 | $235.66 | -76.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TXG forecast.
Our base-case forecast reaches $85.00 around 2029.
Implied market cap at $85.00: $9.93B
The year-by-year forecast shows meaningful upside across the longer horizon, with 2030 average at $113.28 and a max of $186.08 (min $74.64), yielding a ROI of 162.8 and a bullish sentiment. By 2040, the average rises to $277.97 (max $563.65, min $136.31) with a ROI of 544.9, supported by a bullish outlook.
By 2050, the average reaches $730.89 (max $1,672.45, min $328.90) with a ROI of 1595.8, continuing the bullish sentiment. The forecast highlights progressively higher midpoints across key milestones (e.g., 2040 and 2050) and a sustained positive trajectory, though these are estimates and not guarantees. Higher volatility remains a consideration given the broad range of possible outcomes.
Tap a question to reveal the answer.
2030 avg price is $113.28, with a min of $74.64 and a max of $186.08. The forecast shows a ROI of 162.8 and a bullish sentiment for that year.
The forecast shows bullish sentiment across multiple years, with 2027 avg $51.82 (ROI 20.2), 2028 avg $74.06 (ROI 71.8), 2029 avg $96.60 (ROI 124.1), 2030 avg $113.28 (ROI 162.8), 2040 avg $277.97 (ROI 544.9), and 2050 avg $730.89 (ROI 1595.8). These figures indicate upside potential but are estimates, not guarantees.
Yes. The 2050 max forecast is $1,672.45, which implies the possibility of reaching above $1,000 by 2050.
Current price is $43.10 and market capitalization is $5.47B. The rank is 1318.
The 30-day range runs from a low of $32.09 to a high of $57.89.
10x Genomics, Inc. Community Discussion
0Share your 10x Genomics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.